Carla Oliveíra

This study identifies AGR2 as a prognostic biomarker and potential therapeutic target for overcoming drug resistance in HER2-overexpressing cancers.

The paper reanalyzes exome sequencing data from rare disease cases to identify previously undetected copy number variants, resulting in diagnoses for 51 families and partial explanations for 34 individuals.

The paper updates CDH1 variant curation guidelines to resolve conflicting interpretations and reduce variants of uncertain significance for clinical use.

This study identifies CD44v6 expression as a predictor of therapy response and poor prognosis in gastric cancer patients, showing higher expression correlates with worse outcomes and benefit from chemotherapy.